Clovis Oncology Closes $250 Million 144A Notes Offering

August 15, 2019

Willkie represented Clovis Oncology, Inc. in its offering of its 4.50% convertible senior notes due 2024.

On August 13, Willkie client Clovis Oncology, Inc. announced the closing of its offering of $250 million aggregate principal amount of its 4.50% convertible senior notes due 2024 in a Rule 144A offering to qualified institutional buyers. Based in Boulder, CO, Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets.

Willkie previously represented Clovis Oncology in its IPO and several subsequent equity and debt offerings. Willkie has also represented Clovis Oncology in numerous acquisitions and licensing deals of products and businesses.

The Willkie team was led by partner Thomas Mark and associates Annie Barrett, Marisa Weisbaum and Maria LaGumina and law clerk Theodore Witt.